New research indicates that patients who come off popular GLP-1 drugs like semaglutide or tirzepatide can put back on shed pounds much more quickly than those who end conventional diet and exercise regimens.
Findings released in a prominent medical journal demonstrates that while obese individuals frequently drop a large proportion of their total mass while undergoing treatment, the mass returns at an estimated rate of 0.8 kg per month upon discontinuation.
"People purchasing these treatments must be aware of the risk of quick rebound weight gain when the therapy ends," cautioned lead investigator Dr. Susan Jebb.
That rate of regain implies a reversion to starting mass in about one and a half years.
Weighing Approaches
The research, which looked at dozens of studies involving thousands of participants, contrasted the effects of GLP-1 agonists with older methods.
The team emphasize that people who shed pounds through dieting typically have a more gradual weight regain—around 0.1 kg a month—post-intervention.
Explaining the Quick Rebound
Doctors propose the way of the drugs is key to understanding the heightened rebound.
The injections mimic a natural hormone called glucagon-like peptide-1, which moderates appetite.
"Sustained high doses of the hormone concentrations several times higher than normal may cause the body to generate a reduced amount of its own natural hormone, and could lessen responsiveness to its effects," said Dr. Adam Collins, a dietetics expert.
"Discontinuation of this hormone supplement leads to appetite is unsuppressed, making overeating a significant risk."
A Lifelong Issue?
The NHS suggest the jabs for people with obesity-related health risks, alongside recommended lifestyle changes.
A number of clinicians contend that, given the significant potential of weight regain, the treatment might need to be long-term.
This opinion is reinforced by drug manufacturers, who say that the results "underscore the long-term character of obesity," comparing it to managing diseases like high blood pressure.
Patient Testimonies
Individuals who have come off the jabs report a sudden return of hunger.
"I experienced a switch flipping and you're instantly ravenous," described one woman.
This challenge is worsened if patients have not adopted lasting lifestyle or habit modifications during therapy.
Growing Interest
Figures show that a significant number of adults in the UK have tried weight-loss jabs in the past year, with desire remaining high.
- Adoption is more common among women compared to men.
- The middle-aged demographic shows the highest level of interest.
- A large proportion access the medications through private prescriptions rather than public health services.
Ultimately, experts emphasize that while these medications are potent tools for weight loss, they are not a magic fix and long-term success hinges on integrated lifestyle support.
